MCID: ALK016
MIFTS: 45

Alk-Negative Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma 59
Anaplastic Large Cell Lymphoma, Alk-Negative 17 33
Anaplastic Large Cell Lymphoma, Alk Negative 72
Anaplastic Large Cell Lymphoma, Alk-Positive 72
Alk- Anaplastic Large Cell Lymphoma 59
Alk- Alcl 59

Characteristics:

Orphanet epidemiological data:

59
alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

ICD10 33 C84.7
ICD10 via Orphanet 34 C84.7
UMLS via Orphanet 73 C1332078
Orphanet 59 ORPHA300903
UMLS 72 C1332078 C1332079

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk-negative, is related to alk-positive anaplastic large cell lymphoma and lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Prednisone and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and nk cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 33.7 STAT3 ALK
2 lymphoma 31.5 MYC BCL2 BAX ALK
3 peripheral t-cell lymphoma 30.6 CXCR3 CCR4 ALK
4 lymphoma, non-hodgkin, familial 29.9 MYC BCL2L1 BCL2 BAX ALK
5 myeloma, multiple 29.2 STAT3 PMAIP1 MYC BCL2L1
6 anaplastic large cell lymphoma 11.1
7 lymphoma, hodgkin, classic 10.6
8 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.5 MYC BCL2
9 diffuse large b-cell lymphoma of the central nervous system 10.5 MYC BCL2
10 lymphomatoid papulosis 10.4
11 kashin-beck disease 10.3 BCL2 BAX
12 primary mediastinal large b-cell lymphoma 10.3 MYC CD274
13 suppressor of tumorigenicity 3 10.2 MYC BCL2 BAX
14 malignant teratoma 10.2 BCL2 BAX
15 aplastic anemia 10.2
16 myelodysplastic syndrome 10.2
17 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
18 t-cell lymphoma, subcutaneous panniculitis-like 10.2
19 hemophagocytic lymphohistiocytosis 10.2
20 adult t-cell leukemia 10.2
21 lymphoblastic lymphoma 10.2
22 sarcoma 10.2
23 respiratory failure 10.2
24 disseminated intravascular coagulation 10.2
25 capillary leak syndrome 10.2
26 thrombocytopenia 10.2
27 ichthyosis 10.2
28 spindle cell sarcoma 10.2
29 t-cell adult acute lymphocytic leukemia 10.2
30 t-cell leukemia 10.2
31 reticulosarcoma 10.2
32 neuropathy 10.2
33 hypereosinophilic syndrome 10.2
34 47,xyy 10.2
35 granulomatous slack skin disease 10.2
36 ichthyosis, acquired 10.2
37 leukemia, t-cell, chronic 10.2
38 soft tissue sarcoma 10.2
39 systemic capillary leak syndrome 10.2
40 t-cell non-hodgkin lymphoma 10.2
41 rapidly involuting congenital hemangioma 10.2
42 autoimmune lymphoproliferative syndrome, type v 10.1
43 cutaneous t cell lymphoma 10.1
44 lymphoproliferative syndrome 10.1
45 angioimmunoblastic t-cell lymphoma 10.1
46 lymphocytic leukemia 10.1
47 hydronephrosis 10.1
48 malignant fibroxanthoma 10.1
49 rhabdomyosarcoma 10.1
50 syphilis 10.1

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 BAX BCL2 BCL2L1 DUSP22
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 BAX BCL2 BCL2L1 DUSP22 MYC TP63

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 ADA ALK BAX BCL2 BCL2L1 CD274
2 growth/size/body region MP:0005378 10.18 ADA ADARB1 ALK BAX BCL2 BCL2L1
3 endocrine/exocrine gland MP:0005379 10.15 ADA ALK BAX BCL2 BCL2L1 DPP4
4 hematopoietic system MP:0005397 10.11 ADA BAX BCL2 BCL2L1 CCR4 CD274
5 immune system MP:0005387 10.1 ADA BAX BCL2 BCL2L1 CCR4 CD274
6 mortality/aging MP:0010768 10.06 ADA ADARB1 ALK BAX BCL2 BCL2L1
7 integument MP:0010771 9.91 ALK BCL2 BCL2L1 CD274 MYC STAT3
8 neoplasm MP:0002006 9.81 ALK BAX BCL2 BCL2L1 CXCR3 FRK
9 muscle MP:0005369 9.8 ADA ADARB1 BAX BCL2 MYC STAT3
10 reproductive system MP:0005389 9.56 ADA ALK BAX BCL2 BCL2L1 MYC
11 respiratory system MP:0005388 9.17 ADA ALK BAX CCR4 CXCR3 STAT3

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
3
Pirarubicin Investigational Phase 4 72496-41-4
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6 Hormone Antagonists Phase 3
7 Alkylating Agents Phase 3
8 Antineoplastic Agents, Phytogenic Phase 3
9 Hormones Phase 3
10 glucocorticoids Phase 3
11 Tubulin Modulators Phase 3
12 Anti-Inflammatory Agents Phase 3
13 Immunologic Factors Phase 3
14 Immunosuppressive Agents Phase 3
15 Antineoplastic Agents, Hormonal Phase 3
16 Topoisomerase Inhibitors Phase 3
17 Antineoplastic Agents, Alkylating Phase 3
18 Antimitotic Agents Phase 3
19 Antirheumatic Agents Phase 3
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
21
Liposomal doxorubicin Phase 3 31703
22 Anti-Bacterial Agents Phase 3
23 Antibiotics, Antitubercular Phase 3
24
alemtuzumab Approved, Investigational Phase 2 216503-57-0
25
nivolumab Approved Phase 2 946414-94-4
26
Ceritinib Approved Phase 1, Phase 2 1032900-25-6
27
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
28
leucovorin Approved Phase 2 58-05-9 143 6006
29
Etoposide Approved Phase 2 33419-42-0 36462
30
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
31
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
33
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
34
Ifosfamide Approved Phase 2 3778-73-2 3690
35
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
36
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Ichthammol Approved Phase 2 8029-68-3
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
40
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
41
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
42 Tin Fluorides Phase 2
43 Angiogenesis Inhibitors Phase 1, Phase 2
44 Angiogenesis Modulating Agents Phase 1, Phase 2
45 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
46 Folic Acid Antagonists Phase 2
47 Folate Phase 2
48 Vitamin B Complex Phase 2
49 Vitamin B9 Phase 2
50 Etoposide phosphate Phase 2

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
4 Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL) Completed NCT01679860 Phase 2 Clin B (CHOP- CAMPATH) Chemo-immunotherapy
5 A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT03719898 Phase 2 Brigatinib
6 Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) Recruiting NCT03703050 Phase 2 Nivolumab cohort 1;Nivolumab cohort 2
7 A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3) Recruiting NCT03505554 Phase 2 Lorlatinib
8 A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
9 Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Recruiting NCT02572453 Phase 2 Onalespib
10 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Recruiting NCT02419287 Phase 2 crizotinib
11 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
12 A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy Active, not recruiting NCT02462538 Phase 1, Phase 2 Brentuximab vedotin;Imatinib
13 A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) Suspended NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
14 A Phase 1 Study of Interleukin-15 in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies. Recruiting NCT03905135 Phase 1 rhIL-15
15 Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL) Completed NCT01366170
16 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma Recruiting NCT03603847

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

41
T Cells, Breast, Nk Cells, Bone, Lymph Node, B Cells, Myeloid

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 116)
# Title Authors PMID Year
1
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. 38
30873584 2019
2
Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. 38
31278738 2019
3
Primary ALK-negative anaplastic large cell lymphoma with extensive bone involvement mimicking multiple myeloma and metastatic carcinoma. 38
31093934 2019
4
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. 38
31101622 2019
5
ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. 38
30685783 2019
6
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. 38
30829413 2019
7
A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT. 38
30562196 2019
8
Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. 38
30407628 2019
9
[Clinicopathological characteristics of adult T cell leukemia/lymphoma]. 38
30641639 2019
10
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. 38
30151671 2018
11
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype. 38
29898383 2018
12
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. 38
29449683 2018
13
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. 38
29758012 2018
14
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. 38
29359238 2018
15
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. 38
29026208 2018
16
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as Disseminated Intravascular Coagulation and Hemophagocytic Lymphohistiocytosis: A Potentially Fatal Presentation. 38
29850298 2018
17
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. 38
28370436 2017
18
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. 38
28381153 2017
19
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. 38
29100307 2017
20
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. 38
28344319 2017
21
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. 38
28522440 2017
22
Indolent ALK-negative anaplastic large-cell lymphoma, DUSP22 rearranged, with an unusual immunophenotype in a human immunodeficiency virus patient. 38
28042680 2017
23
PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature. 38
28013563 2017
24
Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. 38
27480544 2017
25
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. 38
28139895 2017
26
[Primary ALK-negative anaplastic large cell lymphoma of breast: report of a case]. 38
28072980 2017
27
Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation. 38
28003232 2016
28
[Granulomatous slack skin associated with ALK-negative anaplastic large cell lymphoma]. 38
28056306 2016
29
[Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]. 38
27995879 2016
30
Cyclin D1 expression in peripheral T-cell lymphomas. 38
27469326 2016
31
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. 38
27460479 2016
32
[Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma]. 38
27587245 2016
33
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. 38
27209536 2016
34
Cytological Diagnosis of Bilateral Breast Implant-Associated Lymphoma of the ALK-Negative Anaplastic Large-Cell Type. Clinical Implications of Peri-Implant Breast Seroma Cytological Reporting. 38
27079579 2016
35
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. 38
27263791 2016
36
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. 38
26861608 2016
37
Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas. 38
26922803 2016
38
Overexpression of TMOD1 is associated with enhanced regional lymph node metastasis in human oral cancer. 38
26718916 2016
39
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. 38
26598546 2016
40
Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma. 38
27695344 2016
41
ALK-negative anaplastic large-cell lymphoma. 38
26769771 2016
42
Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. 38
26809026 2016
43
Successful Cord Blood Stem Cell Transplantation for an Adult Case of Chronic Active Epstein-Barr Virus Infection. 38
27904117 2016
44
Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. 38
26379152 2015
45
Extracavitary/solid variant of primary effusion lymphoma presenting as a gastric mass. 38
26407759 2015
46
ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. 38
25975837 2015
47
[Expression of microRNA in ALK-negative anaplastic large cell lymphoma and CD30-positive peripheral T cell lymphoma, not otherwise specified]. 38
26705180 2015
48
Axillary Lymphadenopathy: An Outstanding Presentation for Breast Implant-Associated ALK-Negative Anaplastic Large Cell Lymphoma. 38
25829459 2015
49
Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray. 38
26281838 2015
50
PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. 38
26187868 2015

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 STAT3 PMAIP1 MYC CXCR3 CCR4 BCL2L1
2
Show member pathways
13.63 STAT3 MYC CXCR3 CCR4 BCL2L1 BCL2
3
Show member pathways
12.93 STAT3 MYC CCR4 BCL2L1 BCL2 BAX
4
Show member pathways
12.81 STAT3 PMAIP1 MYC BCL2L1 BCL2 BAX
5
Show member pathways
12.72 TP63 PMAIP1 MYC BCL2L1 BCL2 BAX
6
Show member pathways
12.66 STAT3 BCL2L1 BCL2 BAX ALK
7
Show member pathways
12.65 STAT3 PMAIP1 BCL2L1 BCL2 BAX
8 12.59 STAT3 PMAIP1 MYC BCL2L1 BCL2 BAX
9
Show member pathways
12.55 STAT3 MYC BCL2L1 BCL2
10
Show member pathways
12.55 STAT3 MYC BCL2L1 BCL2 BAX
11
Show member pathways
12.52 STAT3 BCL2L1 BCL2 BAX
12 12.49 TP63 STAT3 MYC BCL2
13
Show member pathways
12.42 STAT3 MYC BCL2L1 BCL2 BAX
14
Show member pathways
12.36 STAT3 MYC BCL2L1 BCL2
15
Show member pathways
12.36 STAT3 MYC BCL2L1 BAX
16 12.27 STAT3 PMAIP1 CCR4 BAX
17
Show member pathways
12.24 PMAIP1 MYC BCL2L1 BCL2 BAX
18
Show member pathways
12.17 MYC BCL2L1 BCL2 BAX
19 12.15 STAT3 MYC BCL2L1 BAX
20 12.11 MYC BCL2L1 BCL2 BAX
21
Show member pathways
12.03 STAT3 MYC BCL2 BAX
22 12.03 PMAIP1 MYC BCL2L1 BCL2 BAX
23
Show member pathways
12.02 STAT3 MYC BCL2
24 12.02 TP63 STAT3 MYC
25 12.02 TP63 PMAIP1 BCL2 BAX
26
Show member pathways
11.94 BCL2L1 BCL2 BAX
27 11.94 PMAIP1 MYC BCL2 BAX
28 11.92 STAT3 MYC BCL2L1 BCL2
29
Show member pathways
11.9 TP63 PMAIP1 BAX
30 11.87 STAT3 BCL2 BAX
31
Show member pathways
11.8 STAT3 MYC BCL2L1
32
Show member pathways
11.8 STAT3 MYC BCL2L1 BCL2
33 11.76 PMAIP1 MYC BAX
34 11.76 MYC BCL2L1 BCL2 BAX
35 11.74 MYC BCL2 ADA
36
Show member pathways
11.68 PMAIP1 BCL2L1 BCL2 BAX
37
Show member pathways
11.67 MYC BCL2L1 BCL2
38
Show member pathways
11.65 TP63 PMAIP1 BCL2L1 BCL2 BAX
39 11.6 PMAIP1 BCL2L1 BCL2 BAX
40 11.53 BCL2L1 BCL2 BAX
41 11.53 STAT3 MYC BCL2L1
42 11.48 MYC BCL2 BAX
43
Show member pathways
11.47 STAT3 MYC BCL2L1
44 11.44 MYC BCL2 BAX
45 11.36 PMAIP1 BCL2L1 BAX
46 11.33 STAT3 MYC BCL2L1
47 11.27 BCL2L1 BCL2 BAX
48
Show member pathways
11.26 PMAIP1 BCL2L1 BCL2 BAX
49
Show member pathways
11.2 STAT3 MYC BCL2L1 BCL2
50 11.17 MYC BCL2 BAX

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.56 CXCR3 CD274 CCR4 ADA
2 pore complex GO:0046930 9.16 BCL2 BAX
3 Bcl-2 family protein complex GO:0097136 8.96 BCL2L1 BAX
4 mitochondrial outer membrane GO:0005741 8.92 PMAIP1 BCL2L1 BCL2 BAX

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 STAT3 MYC BCL2L1 BCL2 ADA
2 response to drug GO:0042493 9.96 STAT3 MYC BCL2 ADA
3 cytokine-mediated signaling pathway GO:0019221 9.95 STAT3 MYC BCL2L1 BCL2
4 apoptotic process GO:0006915 9.93 TP63 PMAIP1 CXCR3 BCL2L1 BCL2 BAX
5 regulation of cell cycle GO:0051726 9.89 STAT3 BCL2 BAX ADARB1
6 negative regulation of cell migration GO:0030336 9.85 DUSP22 BCL2 ADARB1
7 cellular response to hypoxia GO:0071456 9.85 PMAIP1 MYC BCL2
8 regulation of apoptotic process GO:0042981 9.85 TP63 PMAIP1 BCL2L1 BCL2 BAX ALK
9 male gonad development GO:0008584 9.83 BCL2L1 BCL2 BAX
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 BCL2L1 BCL2 BAX
11 response to radiation GO:0009314 9.75 CCR4 BCL2L1 BCL2
12 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.73 BCL2L1 BCL2 BAX
13 response to cytokine GO:0034097 9.73 STAT3 CD274 BCL2L1 BCL2
14 response to gamma radiation GO:0010332 9.72 MYC BCL2 BAX
15 regulation of mitochondrial membrane potential GO:0051881 9.71 BCL2L1 BCL2 BAX
16 ovarian follicle development GO:0001541 9.71 MYC BCL2L1 BCL2 BAX
17 mitochondrion morphogenesis GO:0070584 9.68 BCL2L1 BAX
18 homeostasis of number of cells GO:0048872 9.68 CCR4 BAX
19 B cell homeostasis GO:0001782 9.68 BCL2 BAX
20 positive regulation of smooth muscle cell migration GO:0014911 9.67 MYC BCL2
21 positive regulation of protein oligomerization GO:0032461 9.67 PMAIP1 BAX
22 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.67 TP63 PMAIP1 BCL2
23 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.66 BCL2 BAX
24 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.65 TP63 BAX
25 apoptotic mitochondrial changes GO:0008637 9.65 BCL2L1 BCL2 BAX
26 hypothalamus development GO:0021854 9.64 MYC BAX
27 positive regulation of ATP biosynthetic process GO:2001171 9.64 STAT3 MYC
28 regulation of protein heterodimerization activity GO:0043497 9.63 BCL2 BAX
29 regulation of protein homodimerization activity GO:0043496 9.62 BCL2 BAX
30 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0001844 9.62 PMAIP1 BAX
31 neuron apoptotic process GO:0051402 9.62 TP63 BCL2L1 BCL2 BAX
32 leukocyte homeostasis GO:0001776 9.61 BCL2 BAX
33 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.58 DPP4 ADA
34 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.56 PMAIP1 BCL2L1 BCL2 BAX
35 regulation of nitrogen utilization GO:0006808 9.52 BCL2 BAX
36 positive regulation of developmental pigmentation GO:0048087 9.51 BCL2 BAX
37 release of cytochrome c from mitochondria GO:0001836 9.46 PMAIP1 BCL2L1 BCL2 BAX
38 regulation of mitochondrial membrane permeability GO:0046902 9.26 STAT3 PMAIP1 BCL2L1 BCL2
39 cell proliferation GO:0008283 9.17 TP63 STAT3 MYC BCL2L1 BCL2 BAX
40 positive regulation of cell proliferation GO:0008284 10.03 STAT3 MYC DPP4 BCL2L1 BCL2
41 negative regulation of cell proliferation GO:0008285 10.01 STAT3 FRK BCL2 BAX ADARB1

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 TP63 STAT3 DPP4 BCL2L1 BCL2 BAX
2 chemokine receptor activity GO:0004950 9.26 CXCR3 CCR4
3 adenosine deaminase activity GO:0004000 9.16 ADARB1 ADA
4 BH3 domain binding GO:0051434 8.8 BCL2L1 BCL2 BAX

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....